It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Hospital uptake of newer antibiotics to treat multidrug-resistant gram-negative bacteria was low over a 5-year period, according to a retrospective cohort study. Fully 41.5% of episodes of ...

GR was a paid consultant to Cubist Pharmaceuticals on a previous project on "Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant pseudomonas aeruginosa ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

A new antibiotic against gram-negative bacteria hasn’t been developed since the 1970s. Now, a European research team led by Swedish scientists has discovered multi-drug-resistant bug-killing ...

“Antibiotics have selectivity for bacteria over human cells, but most of them cause great devastation to our microbiome,” said Paul Hergenrother, a chemist at the University of Illinois ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Despite international efforts to reduce the increasing threat of antibiotic resistance, multi-drug resistant bacteria are continuing to endanger the global population. Gram-negative bacteria are ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

Zaynich could play a key role in treating patients suffering from complicated urinary tract infections caused by ...